Under the pilot project, Novartis will pay Compugen a one-time fee for the results and obtain exclusive rights to them. Compugen will retain all rights to the platform it plans to develop under the collaboration. Additional information about this platform was not disclosed. Also not immediately clear is how this platform will differ from Compugen's existing LEADS technology, which analyzes array and other data -- inlcuding those supplied by Novartis.
Indeed, in August 2001, Novartis licensed Compugen's LEADS platform and asked the company to design DNA chips. The companies broadened their collaboration to include target validation and RNA interference in September 2002.